Clostridioides difficile
Vaccines Forecast
Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated infectious diarrhoea in the United States, and there is still no licensed vaccine. The field has been reset by a single large Phase 3 and a re-licensed European asset. VAMV001 is VacZine Analytics' independent commercial assessment of what a first-in-class C. difficile vaccine could be worth, and to whom.
- Format
- PDF executive deck + Excel forecast model
- Markets modelled
- United States first, then major markets
- Scenarios
- Uptake, pricing, launch & efficacy
- Approach
- Target-population demand model
- Edition
- Title refresh (first edition 2007)
- Publication
- Q4 2026
- Availability
- Syndicated / bespoke
(CDC; 476,400 in 2011)
go on to a recurrence
Pfizer's Phase 3 BEETHOVEN trial
to date
A toxin-driven hospital infection that treatment alone has not contained
This section sets out the disease background and epidemiology of Clostridioides difficile infection, and why prevention, rather than further treatment, is the remaining unmet need.
Pathogen overview - Clostridioides difficile
Clostridioides difficile is a spore-forming, toxin-producing anaerobic bacterium and the leading cause of healthcare-associated infectious diarrhoea in the United States. Disease is driven by toxins A and B, with a binary toxin added in hypervirulent strains, and it typically follows disruption of the gut microbiome by antibiotics. CDC's first national estimate put the 2011 burden at 453,000 cases, 83,000 first recurrences and 29,300 deaths. A later CDC analysis estimated 476,400 cases in 2011 and 462,100 in 2017.
The burden has shifted, not disappeared. Between 2011 and 2017 healthcare-associated CDI fell by 36%, but community-associated CDI was unchanged. Age is the dominant risk factor, with an incidence rate ratio of 8.65 for adults aged 65 and over, and about one in five patients with a first episode goes on to a recurrence. Acute-care costs have been estimated at up to $4.8 billion a year in the United States. In Europe the burden is also substantial, with surveillance led by ECDC, and the report treats Europe from the published surveillance record.
Treatment has not solved recurrence. Antibiotics clear the infection but do not prevent it returning, and the US now has approved microbiome-based therapies aimed at reducing recurrence. None of these addresses the underlying exposure risk in hospitalised, care-home, antibiotic-exposed and immunosuppressed patients, which is why a vaccine for adults aged 65 and over and other high-risk groups remains the central commercial question.
One Phase 3 programme now carries the field
Pfizer's second-generation candidate is in a 32,500-participant Phase 3, and a re-licensed European asset is expected in the clinic around 2027. Earlier programmes have stalled or been discontinued, so the near-term market is shaped largely by a single readout.
-
PfizerPhase 3PF-07831694 (BEETHOVEN, NCT07282665) Second-generation toxoid vaccine
A placebo-controlled Phase 3 in about 32,500 adults aged 65 and over, started in December 2025, with primary completion registered for December 2028. The primary endpoint is the first episode of medically attended, clinically meaningful primary CDI, with surveillance of up to about 3.5 years. -
PfizerFirst generation, 2022First-generation C. difficile vaccine (CLOVER) Missed primary endpoint
The CLOVER Phase 3 did not meet its primary endpoint. Pfizer reported 100% efficacy against medically attended CDI (0 of 17 vaccine-group cases were medically attended, versus 11 of 25 in the placebo group) and a 75% reduction in the median duration of infection, which underpins the second-generation programme. -
Elaris (Vienna)PreclinicalNext-generation candidate based on Valneva VLA84 technology Exclusive global licence, March 2026
Elaris holds an exclusive global licence to Valneva's C. difficile technology and is adding proprietary components to broaden protection. IND-enabling development is under way, with clinical studies targeted for around 2027. -
NovavaxPreclinicalMultivalent polypeptide vaccine Patent granted
A granted patent covers a multivalent polypeptide combining CDT, toxin A and portions of toxin B, supported by mouse lethal-toxin challenge studies. No public clinical timeline. -
Idorsia, Vaxxilon, MatrivaxEarlier stageEarlier-stage programmes Various
Earlier-stage candidates are tracked in the report alongside programmes that have been discontinued, including Sanofi's Cdiffense vaccine, which was stopped after its Phase 3 trial in 2017.
The commercial picture is being reset by one large Phase 3 and a re-licensed European asset. VAMV001 models target populations, second-generation versus first-generation expectations after CLOVER, and uptake and value scenarios for a first-in-class vaccine, United States first.
Six analytical layers - one commercial picture
A target-population demand model for a first-in-class C. difficile vaccine, with scenarios that bracket the Phase 3 outcome and a pipeline review updated to the latest registry and company data.
Demand and revenue forecast for a first-in-class C. difficile vaccine, United States first, then other major markets.
Scenarios on efficacy, uptake, pricing and launch timing, bracketing the outcome of the Phase 3 readout.
Adults aged 65 and over and other high-risk groups, including hospitalised, care-home, antibiotic-exposed and immunosuppressed patients.
Registry-verified review of Pfizer, Elaris, Novavax and earlier-stage programmes, with discontinued programmes tracked.
What the CLOVER result means for expectations of second-generation vaccines, and where value is won or lost.
CDI burden and the hospital to community shift, updated to the latest available data.
A glimpse of the commercial model
The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, scenario assumptions and market data are in the licensed model.
| Target population | Geography | Setting | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| Adults aged 65 and over | United States | Community and long-term care | Pre-licensure | Modelled |
| Hospitalised high-risk adults | United States | Acute care | Pre-licensure | Modelled |
| Immunosuppressed adults | United States | Specialist care | Pre-licensure | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All markets | All settings | All scenarios | $███m |
What you receive
An executive presentation and a fully interactive forecast model, built for organisations evaluating the first-in-class C. difficile vaccine opportunity.
- Executive presentation (PDF) - disease burden, pipeline and the full commercial assessment, with supporting narrative and references
- Excel forecast model - interactive scenario dashboard with demand and revenue by target population and year
- Scenario set - efficacy, uptake, pricing and launch-timing scenarios with documented assumptions and sources
- Pipeline and competitor intelligence - registry-verified review of the clinical field, including discontinued programmes
- Updated epidemiology - CDI burden and the hospital to community shift, updated to the latest available data
- Briefing call - a walkthrough of the findings with the analyst team on request
Built for organisations weighing the C. difficile vaccine opportunity
Most valuable to teams evaluating the market against their own pipeline, BD ambitions or investment thesis ahead of the Phase 3 readout.
Vaccine developers
Positioning and commercial feasibility for C. difficile candidates at any stage, informed by the Pfizer Phase 3 and the CLOVER result.
Corporate strategy & BD
Size and structure the opportunity, and test licensing and partnering options ahead of a late 2028 readout.
Investors & analysts
Independent assessment of pipeline risk and commercial upside for due diligence on Pfizer, Elaris, Valneva and other entrants.
Hospital & infection-control stakeholders
Demand modelling for hospitalised, care-home and antibiotic-exposed patient groups.
Researchers & academia
Disease burden, epidemiology and R&D landscape for grant and translational research planning.
Market access & policy
Value and pricing context for a first-in-class vaccine in older adults and high-risk groups.
VAMV001 is the Q4 2026 refresh of VacZine Analytics' Clostridioides difficile vaccines title, first published in 2007. It assesses the commercial opportunity for a first-in-class vaccine, covering target populations, expectations for second-generation candidates after CLOVER, and uptake and value scenarios, United States first.
The analysis draws on CDC burden estimates and a pipeline verified against trial registries and company disclosures. Where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest in the Q4 2026 syndicated MarketVIEW edition. Single-licence and multi-user options are available on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc C. difficile analysis, and a briefing call is included on request.